[
  {
    "ts": "2025-09-11T16:55:45+00:00",
    "headline": "Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market",
    "summary": "Regeneron’s pozelimab and Alnylam Pharmaceuticals’ cemdisiran work through mediating C5 complement inhibition.",
    "url": "https://www.clinicaltrialsarena.com/analyst-comment/phase-iii-regeneron-pozelimab-cemdisiran-mg/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "44f368c5-7680-3d9b-914a-6e9191e35186",
      "content": {
        "id": "44f368c5-7680-3d9b-914a-6e9191e35186",
        "contentType": "STORY",
        "title": "Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market",
        "description": "",
        "summary": "Regeneron’s pozelimab and Alnylam Pharmaceuticals’ cemdisiran work through mediating C5 complement inhibition.",
        "pubDate": "2025-09-11T16:55:45Z",
        "displayTime": "2025-09-11T16:55:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/9a5361565f3d9ef00aa583e067cf2230",
          "originalWidth": 1440,
          "originalHeight": 960,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3JhsP388.1vmPIkse3cx5g--~B/aD05NjA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/9a5361565f3d9ef00aa583e067cf2230.cf.webp",
              "width": 1440,
              "height": 960,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FTFeyINhFZtfwndDQ6fUqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/9a5361565f3d9ef00aa583e067cf2230.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/analyst-comment/phase-iii-regeneron-pozelimab-cemdisiran-mg/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/phase-iii-success-regeneron-signals-165545307.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-11T08:57:00+00:00",
    "headline": "Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?",
    "summary": "Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "url": "https://finance.yahoo.com/news/strength-seen-travere-tvtx-26-085700485.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2395bddf-2a6b-327f-83d6-a5ef9702f9a0",
      "content": {
        "id": "2395bddf-2a6b-327f-83d6-a5ef9702f9a0",
        "contentType": "STORY",
        "title": "Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?",
        "description": "",
        "summary": "Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
        "pubDate": "2025-09-11T08:57:00Z",
        "displayTime": "2025-09-11T08:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/02fae043f47d40eaef946248178af566",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KWalTk1Kn57pyg3V1TuOmg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/02fae043f47d40eaef946248178af566.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vs6Jud9t2LbCaEsDaL.2JQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/02fae043f47d40eaef946248178af566.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strength-seen-travere-tvtx-26-085700485.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strength-seen-travere-tvtx-26-085700485.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TVTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]